Zhang Lu, Yang Yueying, Tan Jianjun
Department of Biomedical Engineering, College of Chemistry and Life Science, Beijing University of Technology, Beijing 100124, China.
Department of Biomedical Engineering, College of Chemistry and Life Science, Beijing University of Technology, Beijing 100124, China; Beijing International Science and Technology Cooperation Base for Intelligent Physiological Measurement and Clinical Transformation, Beijing 100124, China.
Drug Discov Today. 2025 Feb;30(2):104290. doi: 10.1016/j.drudis.2025.104290. Epub 2025 Jan 17.
Current therapeutic drugs are inadequate for curing tumors, highlighting the need for novel tumor drugs. The advancement of single-cell RNA sequencing (scRNA-seq) technology offers new opportunities for tumor drug discovery. This technology allows us to explore tumor heterogeneity and developmental mechanisms at the single-cell level. In this review, we outline the application of scRNA-seq in tumor drug discovery stages, including elucidating tumor mechanisms, identifying targets, screening drugs, and understanding drug action and resistance. We also discuss the challenges and future prospects of using scRNA-seq in drug development, providing a scientific foundation for advancing tumor therapies.
目前的治疗药物在治愈肿瘤方面存在不足，这凸显了新型肿瘤药物的必要性。单细胞RNA测序（scRNA-seq）技术的进步为肿瘤药物发现提供了新的机遇。这项技术使我们能够在单细胞水平上探索肿瘤异质性和发育机制。在本综述中，我们概述了scRNA-seq在肿瘤药物发现阶段的应用，包括阐明肿瘤机制、识别靶点、筛选药物以及了解药物作用和耐药性。我们还讨论了在药物开发中使用scRNA-seq的挑战和未来前景，为推进肿瘤治疗提供科学依据。
